ST生物(000504.SZ):子公司與湖南醫藥簽訂戰略合作協議
格隆匯 10 月 22日丨ST生物(000504.SZ)公佈,2020年10月21日,公司全資子公司南華幹細胞再生醫學臨牀轉化研究中心有限責任公司(“南華幹細胞轉化”)與湖南省醫藥銷售有限公司(“湖南醫藥”)簽署《戰略合作協議》,就醫學研究和開發,醫療器械和設備、耗材和試劑等產品的購銷建立廣泛合作。
湖南醫藥充分發揮其在產品和貨源的優勢,南華幹細胞轉化充分利用其醫學研究資源優勢、市場網絡和營銷力量,共同進行產品的推廣和開發。
雙方通過此次戰略合作,以進一步提升運營效率,降低運營成本,實現雙方未來市場發展並獲得更大市場份額,為雙方進一步深化合作創造更大的商業價值。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.